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Based on the current literature, we aimed to provide an overview on Human Papillomavirus prevalence in normal pregnancies and
pregnancies with adverse outcome. We conducted a systematic literature search in PubMed and Embase. Data extracted from the
articles and used for analysis included HPV prevalence, pregnancy outcome, geographical location, investigated tissue types, and
HPV detection methods. The overall HPV prevalence in normal full-term pregnancies was found to be 17.5% (95% CI; 17.3–17.7)
for cervix, 8.3% (95% CI; 7.6–9.1) for placental tissue, 5.7% (95% CI; 5.1–6.3) for amniotic fluid, and 10.9% (95% CI; 10.1–11.7) for
umbilical cord blood. Summary estimates for HPV prevalence of spontaneous abortions and spontaneous preterm deliveries, in
cervix (spontaneous abortions: 24.5%, and preterm deliveries: 47%, resp.) and placenta (spontaneous abortions: 24.9%, and preterm
deliveries: 50%, resp.), were identified to be higher compared to normal full-term pregnancies (𝑃 < 0.05 and 𝑃 < 0.0001). Great
variation inHPV prevalence was observed between study populations of different geographical locations.This review demonstrates
an association between spontaneous abortion, spontaneous preterm delivery, and the presence of HPV in both the cervix and the
placenta. However, a reliable conclusion is difficult to draw due to the limited number of studies conducted on material from
pregnancies with adverse outcome and the risk of residual confounding.
1. Introduction
Intrauterine infection by bacteria is well established as a
pathway leading to spontaneous abortion and spontaneous
preterm birth [1, 2]. Other pathways, however, may be
equally important including decidual hemorrhage, cervical
disorders, genetic components, and environmental exposures
like smoking [3].Much less is known about viral infection and
adverse pregnancy outcome. Human Papillomavirus (HPV),
which is known as awell-established cause for cervical cancer,
does though constitute a candidate. The over 180 known
HPV-types are small, double-stranded DNA viruses with a
circular genome of nearly 8,000 base pairs. HPV infections
are common, but about 90% of all infections can be cleared
within less than 2 years by unknown mechanisms [4–6].
HPV-6 and HPV-11 are the most common low-risk types and
are found to be causative for genital warts [6]. The cancer
associated high-risk types include HPV-16 and HPV-18 [6]
and there is growing evidence of HPV infections playing a
relevant role in other anogenital and head and neck cancers
[7–9]. Worth to mention is also the morbidity of cutaneous
HPV lesions, particularly in immunosuppressed people [9].
Pregnancy has previously proven to be a state of mild
immunosuppression due to the decrease in the number of
natural killer cells [10], possibly making pregnant women
more prone to infections with, for example, HPV. Various
immunological theories have been discussed to explain the
possibility for pregnancy and the survival of the “semiallo-
geneic” fetus. Theories include immunological privilege in
the uterus, antigenic immaturity of the fetus, and maternal
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immunosuppression during pregnancy [11]. While attempt-
ing to explain the immunological basis of normal pregnancy,
the argumentation may have implications for the generation
of immune responses to pathogens infecting the placenta, as
viruses seem to face similar confrontations like the invading
trophoblast [11]. Thus, it is not surprising that viruses take
up some of the same strategies to avoid immune detection
as do trophoblast cells [12]. Also there is some evidence that
elevated steroid hormone levels during pregnancy influence
the increase of HPV virus replication by interacting with hor-
mone response elements in the viral genome, thereby giving
another possible explanation for the higher incidence of HPV
infection during pregnancy [13, 14]. In 2014, Liu et al. [15] con-
ducted a systematic review on HPV prevalence in pregnant
and nonpregnant women and reported an increased risk of
HPV infection in pregnant women, thereby supporting the
debate of how far HPVmay be involved in adverse pregnancy
outcomes. Various authors report an infection with HPV
during pregnancy to be associated with the risk of sponta-
neous abortion, spontaneous preterm delivery, and placental
abnormalities [16–21]. HPV DNA has been detected in the
cervix [13, 21–23], fetal membranes [24], amniotic fluid [25],
umbilical cord blood [26, 27], and the placenta [13, 18, 27–29].
HPV detection rates range however widely from 6 to 65% and
the results are controversial [13, 18, 20, 22, 23, 27, 30–32].
It is therefore of great interest to examine howwidespread
HPV infections are among pregnant women and whether
or not there is an association between HPV infection
and spontaneous abortion or spontaneous preterm delivery.
Moreover, nowadays there exists a successful vaccination to
prevent infection and disease caused by infection with HPV-
6, HPV-11, HPV-16, and HPV-18. Thus, there might be a
chance to minimize the risk for pregnancy complications
by applying the same or a modified version of vaccination.
Our group studies the impact of placental HPV infection on
spontaneous abortion and preterm delivery. In this context
the aim of this study is to provide an overview of the existing
literature by doing a systematic review on HPV prevalence in
pregnancy.We focused on pregnancies with adverse outcome
and included a discussion of possible factors influencing or
explaining the reported differences in HPV detection rates.
2. Material and Methods
PRISMA andMOOSE guidelines were used where applicable
[33].
2.1. Search Strategy. A systematic literature search was con-
ducted in the PubMed and Embase databases and search
terms were used as follows: (1) “Human papillomavirus
AND pregnancy”; (2) “Human papillomavirus AND preterm
delivery”; (3) “Human papillomavirus AND preterm birth”;
(4) “Human papillomavirus AND abortion”. The search was
restricted to articles in English, on humans and published
between January 1995 and October 2014. The search was
carried out on October 28, 2014.
2.2. Study Selection. In order to identify relevant articles for
whole-paper revision, duplicates were removed and titles and
abstracts were screened based on the following exclusion
criteria: studies investigating cell lines only, HPV vaccines,
or sperm-related aspects, as well as guideline articles, general
articles describing public health, and literature reviews. The
remaining articles were assigned to subsequent whole-paper
revision.These articles were systematically reviewed in accor-
dance with the inclusion and exclusion criteria.The inclusion
criteria were set to the following: studies on asymptomatic
healthy pregnant women and women experiencing a sponta-
neous preterm delivery or spontaneous abortion; investiga-
tion of HPV infection within cervix, placenta, amniotic fluid,
or umbilical cord blood; HPV detection test directly linkable
to index pregnancy. Studies restricted to nonpregnantwomen
or HPV positive women only, case reports, follow-up and
association studies, and in vitro fertilization studies were
excluded.
Studies including women with history of HPV-related
lesions were not excluded, as this will be the case in any
normal study population.There was no restriction for studies
of different geographical origins, the time point of sample
collection, methods of sample collection, and HPV testing
method. Information on the latter was included in Table 1,
characteristics of included studies.
2.3. Data Extraction and Statistics. Data, which includes
information about the investigated tissue types, country
where the study was performed, sample size, sampling time
point, HPV prevalence, and HPV detection method, was
extracted and analyzed using MatLab (version R2011b). Data
from all studies was pooled and women were grouped
according to their pregnancy outcome or the pregnancy
status at time point of sample collection. An overall HPV
prevalence was calculated including 95% confidence interval
(CI) in normal pregnancies and in pregnancies with adverse
outcome.This was done for various tissue types, geographical
origins, time points of sample collection, and HPV detec-
tion methods used. Studies from Mexico and Brazil have
been grouped into “Latin America.” Statistical significance
between two proportions was tested using “Two-sample test
of proportions.” All 𝑃 values were two-sided and 𝑃 < 0.05
was considered significant.
3. Results
3.1. Study Selection. The initial PubMed database search
resulted in the identification of a total of 650 articles
(Figure 1). After removal of duplicates and screening of titles
and abstracts, the remaining 57 articles were subjected to
whole-paper revision (Figure 1). Of these, 42 articles met the
final inclusion criteria and were used for data extraction and
quantitative analyses (Figure 1). The supplementary search
in Embase database was conducted in the same way and
three additional articles were included for data extraction and
quantitative analysis. The 45 articles included investigated
14 470 pregnant women in total, of which 13 757 underwent
normal full-term pregnancies, 145 experienced spontaneous
preterm deliveries, 536 experienced spontaneous abortions,
and 32 had performed an induced abortion. The study
populations were from Europe (𝑛 = 4639) [13, 22, 27, 28,
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Identified:
Removal of duplicates
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Screening of titles/abstracts
Exclusion criteria:
Vaccine-related, sperm-related, cell line, guideline and
review articles
Included:
Excluded:
Screening of whole articles
Inclusion criteria:
Study on asymptomatic pregnant women, HPV infection in
cervix, placenta, amniotic fluid, and umbilical cord blood,
HPV detection test directly linkable to index pregnancy
Included:
Exclusion criteria:
Study on nonpregnant women,
case reports, follow-up and
association studies, IVF studies,
HPV positive women
Excluded:
Studies included in analysis
Included:
Studies included in analysis 1
HPV infection in normal
pregnancies
Included:
Studies included in analysis 2
HPV infection in pregnancies with
adverse outcome
Included:
Studies included in analysis 3
HPV infection in pregnancies with
adverse outcome versus normal
pregnancies
Included:
n = 650
n = 595
n = 57
n = 42
n = 42
n = 42
n = 35 n = 10
n = 15
n = 538
Figure 1: Flow diagram of literature search. The flow diagram shows the search in the PubMed database. A supplementary search in the
Embase database was conducted in the same way and resulted in three additional articles for data extraction and quantitative analysis.
32, 38, 40, 42, 43, 45, 47, 51, 58–60, 62–64, 66, 67], Asia
(𝑛 = 7116) [23, 34, 35, 37, 39, 41, 46, 52, 55, 57, 61], USA
(𝑛 = 1681) [18, 20, 21, 29, 48, 53, 56, 65, 68], and Latin
America (𝑛 = 1034) [36, 44, 49, 50, 54]. Table 1 shows
demographic characteristics, key aspects of study design,
and study strength and potential biases of all included stud-
ies.
3.2. HPV Prevalence in Different Tissue Types of Normal
Full-Term Pregnancies. HPV prevalence in healthy pregnant
women giving birth at term was investigated in 38 of the
45 included studies and provided data on 13 757 pregnant
women. HPV prevalence appears to be highly dependent on
the tissue type tested (Figure 2). In all studies included, HPV
prevalence varied between 2.2% and 75% in cervical tissue,
with a summary estimate of 17.5% (95% CI; 17.3–17.7). In
placental tissue and abortion products, 8.3% (95%CI; 7.6–9.1)
of the analyzed pregnancies were found to be HPV positive
and varied between 0% and 47.2%. HPV prevalence in
amniotic fluid varied between 0% and 25%, with a summary
estimate of 5.7% (95% CI; 5.1–6.3). Finally, umbilical cord
blood was calculated to be HPV positive in 10.9% (95% CI;
10.1–11.7) of all cases and varied between 0% and 57.9%. The
difference between all proportions was significant (𝑃 < 0.05,
𝑃 < 0.001, and 𝑃 < 0.0001, resp.).
3.3. HPV Prevalence in Pregnancies with Adverse Outcome
and Comparison to Normal Pregnancies. HPV prevalence in
pregnancies with adverse outcome, including spontaneous
abortion and spontaneous preterm delivery, was investigated
in 10 of the 45 included studies and provided data on 681
pregnancies. Three studies were investigating cervical HPV
infection and seven studies looking at HPV prevalence in
placental tissue. Details are given in Table 2. Only one study
analyzed HPV prevalence in cervical tissue of spontaneous
abortions and found 24.5% of all cervical samples to be HPV
positive (Table 2). Placental HPV prevalence in spontaneous
abortions varied between 0% and 70.4%, with a summary
estimate of 24.9% (95% CI; 22.4–27.5) (Table 2). HPV preva-
lence in spontaneous preterm deliveries was found to be 47%
(95% CI; 42.3–51.6) in cervix, with a variation between 15.6%
and 67.1% (Table 2). Placental tissue of spontaneous preterm
deliveries was only investigated in one study where a HPV
prevalence of 50% was observed (Table 2).
The overall HPV prevalence in cervical tissue of nor-
mal pregnancies was found to be 17.5% (95% CI; 17.3–17.7)
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Figure 2: HPV prevalence depends on the investigated tissue type.
HPVprevalence in different tissue types of normal pregnancies in%.
38 studies have been included in the present analysis, 𝑁cervix = 32,
𝑁placenta/abortion product = 9, 𝑁amniotic fluid = 4, and 𝑁umbilical cord blood =
7. 𝑁 indicates number of studies included. 𝑛 indicates number of
cases included. ∗𝑃 < 0.05, ∗∗∗𝑃 < 0.001, and ∗∗∗∗𝑃 < 0.0001.
(Figure 2). This is significantly lower than in spontaneous
preterm deliveries (47%, 𝑃 < 0.0001) and spontaneous abor-
tions (24.5%, 𝑃 < 0.05) (Figure 3). An even bigger contrast-
ing picture is seen in placental tissue. Here normal pregnan-
cies are found to be HPV positive in 8.3% (95% CI; 7.6–9.1) of
all cases (Figure 2), whereas placental tissues of spontaneous
preterm deliveries and spontaneous abortions are found to be
positive in 50% (𝑃 < 0.0001) and 24.9% (𝑃 < 0.0001) of cases,
respectively (Figure 3).
3.4. HPV Prevalence in Normal Pregnancies Depends on
Geographical Location. Information on geographical distri-
bution of the investigated studies was collected to see if
ethnicity might be a contributing factor to the great variation
in HPV prevalence observed. The goal of the investigation
was to determine whether women from different countries
may be differentially exposed to HPV and some may thereby
have a higher risk for possible HPV-induced pregnancy defi-
ciencies.
Figure 4 shows the geographical distribution of HPV
prevalence in cervical specimens from women with normal
full-term pregnancies. Here it is clear that pregnant women
fromUSA and Latin America have a significantly higher (𝑃 <
0.0001) HPV prevalence compared to European and Asian
women (Figure 4). Latin America is represented by Mexico
and Brazil and the summary estimate for HPV prevalence
was 35.5% (95% CI; 34.6–36.5). HPV prevalence found in the
included studies varied between 15.2% and 75%.The analysis
of the population from USA found a HPV prevalence of
29.6% (95% CI; 29.5–29.7). Here a variation of 28% to 34.2%
has been reported. The Asian population is represented
by China, Japan, and Korea. The cervical HPV prevalence
in Asia varied between 10.1% and 36.2%, with a summary
estimate of 16.4% (95% CI; 16.3–16.6). The European
population is represented by Spain, France, Italy, Germany,
Belgium, Netherlands, Finland, Switzerland, Austria,
Hungary, Greece, Croatia, Turkey, Poland, and Lithuania and
the HPV prevalence varied between 2.2% and 36.6%, with a
summary estimate of 11% (95% CI; 10.7–11.3). The difference
between all proportions was highly significant (𝑃 < 0.01 and
𝑃 < 0.0001, resp.), meaning that HPV prevalence in pregnant
women is dependent on geographical or ethnical parameters,
with pregnant women from USA and Latin America having
the highest HPVprevalence reported.The same tendency can
be observed in placenta, amniotic fluid, and umbilical cord
blood, but numbers were insufficient for proper analyses.
Variation of HPV prevalence between studies conducted
on different continents can also be observed in studies inves-
tigating pregnancies with adverse outcome (Table 2), but a
proper analysis is difficult due to the small number of studies.
However, it can be stated that studies from USA consistently
report a significantly higher HPV prevalence in spontaneous
abortions and spontaneous preterm deliveries compared to
normal pregnancies, in both cervical and placental tissue [18,
20, 21, 29]. European studies vary a lot in their HPV preva-
lence found in placenta, which makes it difficult to estimate
the risk of a HPV infection for European pregnant women.
There are no studies conducted on cervical specimens of
spontaneous abortions or spontaneous preterm deliveries in
Europe. Asian and Latin American studies are also limited
[35, 36] and a conclusion of the risk of HPV infection for
pregnant women is not possible. It can though be speculated
whether the relatively high HPV prevalence found in the
Latin American population of normal pregnancies (Figure 4)
may influence the pregnancy outcome in those countries.
3.5. Influence of the Time Point of Sample Collection and
the HPV Detection Method on HPV Prevalence. There are
multiple factors that may influence HPV prevalence. For the
present analysis, data on the time point of sample collec-
tion and the HPV detection methods used were collected.
Figure 5(a) shows cervical HPV prevalence in relation to
the time point of sample collection. Samples from the first
trimester of pregnancy were found to be HPV positive in
23.9% (95% CI; 23.4–24.4) of all cases and showed a variation
between 1.1% and 41.2%. Samples taken at birth were tested
positive in 21.7% (95% CI; 21.3–22.2) of all cases. Here HPV
prevalence varied between 12.6% and 30.2%. The second and
third trimester as well as postpartum samples showed a HPV
prevalence of 16.7% (95% CI; 16.5–17.0), 15.2% (95% CI; 14.9–
15.6), and 17.3% (95% CI; 16.7–17.9). HPV prevalence varied
between 2.2% and 40%, 5.2% and 75%, and 6.2% and 27%.The
difference between proportionswas significant (𝑃 < 0.05,𝑃 <
0.01,𝑃 < 0.001, and𝑃 < 0.0001 resp.). Not significant was the
difference between the proportions for the first trimester and
at birth samples (𝑃 = 0.12), the second trimester and the third
trimester, respectively, and the postpartum period (𝑃 = 0.07
and 𝑃 = 0.39), and the third trimester and the postpartum
period (𝑃 = 0.14).
Also the HPV detection methods used may influence
the found HPV prevalence. Figure 5(b) shows the analysis
of HPV prevalence according to the HPV detection method
used. Hybrid capture assay identified HPV in 26.4% (95%
CI; 25.6–27.2) of all analyzed samples. The HPV prevalence
found varied between 0% and 67.1%. The summary estimate
for HPV prevalence by PCR was calculated to be 15.5% (95%
CI; 15.3–15.8) and varied between studies from 0% to 100%.
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Figure 3: Higher HPV prevalence detected in pregnancies with adverse outcome compared to normal pregnancies. HPV prevalence in
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HPV prevalence identified by DNA chip varied between 0%
and 24.3%, with a summary estimate of 15.1% (95% CI; 15.0–
15.3). Southern blotting was only used in two studies and a
HPV prevalence of 19.9% (95% CI; 18.7–21.0) has been found.
HPV positivity varied between studies from 12% to 34.2%.
The difference between all but one of the proportions was
significant (𝑃 < 0.05, 𝑃 < 0.01, and 𝑃 < 0.0001, resp.). Not
significant was the difference between proportions for PCR
and DNA chip (𝑃 = 0.25). The HPV detection method used
most widely was PCR with 𝑛 = 9674 followed by DNA chip
with 𝑛 = 5461.
4. Discussion
In this quantitative analysis on the prevalence of HPV infec-
tion in normal pregnancies andpregnancieswith adverse out-
come, 45 studies were included and data on 14 470 pregnant
women were analyzed and summarized. HPV prevalence in
normal pregnancies was found to vary between tissue types
and study populations of different geographical locations.
The highest HPV prevalence could be reported in cervix
(17.5%; 95% CI; 17.3–17.7) and in the population from Latin
America (35.5% (95% CI; 34.6–36.5)) and USA (29.6% (95%
CI; 29.5–29.7)). In comparison to HPV prevalence found in
normal pregnancies, spontaneous abortions and spontaneous
preterm deliveries were found to have higher HPV positive
detection rates (𝑃 < 0.05 and 𝑃 < 0.0001), in both placenta
(spontaneous abortions: 24.9%, and preterm deliveries: 50%
versus 8.3%, resp.) and cervix (spontaneous abortions: 24.5%,
and preterm deliveries: 47% versus 17.5%, resp.). Beyond the
geographical location, the time point of sample collection in
pregnancy as well as the HPV detection methods used may
influence the results on HPV prevalence.
Thepresentwork has someweaknesses. First, heterogene-
ity between studies is a problem. Due to the limited number
of studies conducted within the field of HPV infections and
adverse pregnancy outcomes, inclusion criteria were set rela-
tively widely. This results in a higher number of pregnancies
to analyze but possiblymore heterogeneous study groups and
thereby inflict restricted options to compare directly between
studies. The possibility of forming totally homogenous study
groups is limited by the study quality and information given,
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Figure 5: HPV prevalence depends on time of sample collection and on the applied HPV detection method. (a) Cervical HPV prevalence in
% at different time points of sample collection of normal pregnancies. 25 studies have been included in the present analysis,𝑁
1st trimester = 10,
𝑁
2nd trimester = 10, 𝑁3rd trimester = 18, 𝑁at birth = 4, and 𝑁postpartum = 4. (b) HPV prevalence in % in relation to the detection method used.
Note that only two studies were using Southern blot as their main detection method. 45 studies have been included in the present analysis,
𝑁PCR = 34, 𝑁hybrid capture = 8, 𝑁DNA chip = 5, and 𝑁Southern blot = 2. 𝑁 indicated number of studies included. 𝑛 indicates number of cases
included. ∗𝑃 < 0.05, ∗∗𝑃 < 0.01, ∗∗∗𝑃 < 0.001, and ∗∗∗∗𝑃 < 0.0001; ns: not significant.
and data on patient-level is missing in most, if not all, of the
included studies, which makes controlling for all potential
biases difficult. Table 1 contains potential biases and study
strength for every single study. Potential biases may include
some of the following: unclear inclusion and exclusion
criteria for participating women, missing information on
ethnicity/method of sample collection/time point of sample
collection/mode of delivery, study on highly selected group of
women (cesarean sections, amniocentesis, andCVS) or group
from low socioeconomically regions, and so forth. The inter-
connection between HPV infection and pregnancy outcome
is complex and will therefore most probably not be explain-
able by a single parameter analyzed in the present work.
The analyses done can however point towards a possible
explanation by pregnancy outcome, geographical location, or
HPV detection method. Second, studies vary in their inclu-
sion of women with histories of HPV-related diseases.
Approximately one-third excludes women with HPV-related
lesions, whereas one-third does not exclude but report it and
in the last third of studies this information is missing. Geni-
tal warts and cervical lesions are known to be HPV-related
and a higher percentage of HPV infection would be expected.
Third, studies of adverse pregnancies were few. The actual
HPV prevalence may therefore be higher or lower than the
ones reported in this paper. On the other hand, the present
quantitative analysis includes over 14 000 pregnancies and
covers many different factors possibly influencing HPV pre-
valence, thereby providing a broad overview. Fourth, only
studies published in English were included, which might
limit the results. However, English is the primary common
scientific language and the selection criterion “publications
in English” is therefore considered to be acceptable.
HPV prevalence in pregnant women has been reported to
be higher compared to nonpregnant women [54, 68, 69]. Our
analysis of normal pregnancies, including 38 studies from 19
different countries on four continents, yields an overall HPV
prevalence in the cervix for pregnant women of 17.5% (95%
CI: 17.3–17.7). A worldwide meta-analysis by de Sanjosé et al.
from 2007 reported a prevalence of cervical HPV infections
in nonpregnant women with normal cytology of 10.4%
[70]. The difference between the proportions is noticeable
and it can therefore be speculated if a higher HPV preva-
lence in pregnant women can lead to various pregnancy com-
plications. Pregnancy has previously been described as a state
of immune suppression, facilitating the survival of the “semi-
allogeneic” fetus [52]. The inhibition of the host immune
response may simultaneously increase the susceptibility to
HPV and make it more difficult to clear HPV infections
[54, 69, 71–74]. Higher incidences of HPV infection during
pregnancy may though possibly be explained by the presence
of hormone response elements in the HPV gene that could be
triggered through high steroid levels [13, 14].
An infection with HPV during pregnancy has been asso-
ciated with risk for spontaneous abortion and spontaneous
preterm delivery as well as placental abnormalities [16–21].
Our analysis of 10 studies investigating HPV infection in
pregnancies with adverse outcome found HPV prevalence in
cervix and placenta to be higher than in normal full-term
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pregnancies, supporting the hypothesis of HPV infection
being a risk for pregnancy outcome. Typically the placenta is
a relatively effective barrier guarding against many microbes
[75, 76] and the fetus in utero is therefore well protected.
Nevertheless,multiple studies indicate that viral infection can
impair trophoblast function, potentially contributing to preg-
nancy loss or abnormal implantation [76, 77]. Furthermore,
upper genital tract infection was found to be an important
cause of preterm birth [78].
As previously mentioned, the wide range of HPV preva-
lence found is related to several factors including study
design, geographic and demographic characteristics, choice
of detectionmethod, and risk factor profiles, such asmaternal
age, gestational age, and history of cesarean section [31,
35, 70, 79]. The present work underlines the importance to
consider geographical and demographic variances. The HPV
prevalence around the world was found to differ significantly
(11–35.5%) with Latin America having the highest cervical
HPV prevalence in pregnant women.This is well in line with
the previous literature where Latin America and Africa are
reported as the geographical areas with the highest cervix
cancer rate in the world [8]. North American studies do in
general report a relatively high HPV prevalence [20, 48, 56,
65, 68] and our analysis found a HPV prevalence of 29.6%
(95% CI; 29.5–29.7) for USA. This may be a bit puzzling
since the population in North America due to historical
reasons is expected to resemble the population in Europe. It
can therefore be speculated that studies conducted in North
America include a distinct number of the LatinAmerican and
African American population as has been stated by Gomez
et al. in 2008 [20]. Unfortunately information of ethnicity of
participating women is not available formany of the included
studies, providing a potential bias to the results presented on
geographical origin.
The time point of sample collection during pregnancy is
thought to have an influence on HPV prevalence as differ-
ences in HPV prevalence regarding the trimester tested have
been published [80–83]. Our analysis involved over 13 000
samples and summarized many of the studies investigating
the topic. Hereby the first trimester was found to have the
highest overall HPV prevalence, closely followed by the
samples taken at birth. Analyzed samples collected in the
second and third trimester as well as in the postpartum
period showed lower HPV prevalence. This is contradictory
to studies reporting highest HPV prevalence during the
second [34] and third [54, 65, 68] trimester. On the other
hand, multiple HPV infections were observed in the first
trimester by Yamasaki et al. in 2011 and high-risk HPV-types
were found to be selectively increased in the first trimester
as well [46, 68]. It is however important to keep in mind
that all those time points in reality are time intervals, thereby
making a comparison very difficult. To reduce potential bias
due to uncertainty about the time point of sample collection,
we have chosen to include only studies providing information
on the time point of sample collection. This is the case for 25
of the 45 included studies.
Finally, we compared HPV prevalence with respect to
choice of HPV detection methods, since studies have shown
that HPVDNA detectable and the HPV-genotypes identified
largely depend on this [42]. Our analysis of HPV prevalence
in regard to the applied detection methods revealed
hybrid capture assay as the method detecting most HPV
positive cases (Figure 5(b)). PCR is thought to be the most
sensitive method, detecting less than 10 copies of HPV DNA
[46, 84, 85]. In our analysis the HPV prevalence detected by
PCR was found to be 15.5% (95% CI; 15.3–15.8). Currently an
increasing number of studies use broad spectrum primers
[26, 31, 56] instead of type-specific primers. These are
designed to detect various HPV-types at the same time,
hereby giving a broader picture of the HPV-types present.
The downside of high sensitivities allowed by PCR is the risk
of false-positives due to contamination [84]. It is therefore
crucial to evaluate tissue samples on different molecular
levels, confirming the detected virus to be correctly localized
and active, thus being able to explain the causality of adverse
pregnancy outcome or diseases in general.
Functional studies investigating HPV infection in rela-
tion to pregnancy are limited. Following the detection ofHPV
in placental tissue [17, 18, 62] most research is focused on the
study of HPV infections in trophoblast cell lines. Being one
of the most critical tissues of the placenta, the trophoblast
layer plays an important role in contacting maternal tissues
and serves multiple roles during gestation. Several lines of
evidence point towards the trophoblasts as being the target
cells of placental HPV infection. First, it was shown that HPV
is able to undergo a complete life cycle in trophoblast cell lines
[86, 87]. Second, trophoblast morphology and behavior dur-
ing HPV infection have been investigated, reporting a higher
rate of apoptosis and lower invasion capabilities, agreeing
with possible placental dysfunction and adverse pregnancy
outcome [20]. Third, studies analyzing trophoblast cells
transfected with the HPV genes E5, E6, and E7 report effects
on trophoblastic adhesion and increasedmigratory and inva-
sive properties and may eventually explain potential abnor-
mal implantation due to inappropriate trophoblast spreading
[88]. However, a convincing role for HPV infection in con-
nectionwith spontaneous abortion and spontaneous preterm
delivery, at the molecular level, has still to be demonstrated.
5. Conclusion
Based on the present quantitative analyses it can be concluded
that HPV prevalence is higher in pregnancies with adverse
outcome, such as spontaneous abortion or spontaneous
preterm delivery, compared to women experiencing a normal
full-term pregnancy. HPV infection may therefore be consti-
tuted as a risk for the present pregnancy.
HPV prevalence has been shown to be dependent on
the tissue type tested and the geographical location of the
study population analyzed. However, the number of studies
investigating HPV infection on material from spontaneous
abortions and spontaneous preterm deliveries is very limited
and study groups are heterogeneous which makes a reliable
conclusion difficult. It can be stated that study design is
important, the selection of proper controls is essential, and,
for a valuable comparison between studies, similarity in
samples/patients needs to be controlled as strictly as possible.
Furthermore, one should keep in mind that the simple
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detection of a virus never is equal to a real causative role in
the adverse outcome of a pregnancy or diseases in general.
It is therefore inevitable to study the viral activity and cellu-
lar localization to be able to conclude on the impact for a
given situation.Therefore we recommend including an inves-
tigation of the molecular mechanism of HPV infections in
material of pregnancies with adverse outcome and inviting
researchers to conduct new studies to clarify HPV’s impact
on spontaneous abortion and spontaneous preterm delivery.
As a consequence of the aforementioned limitations our
study group has initiated a prospective study addressing the
complexity of HPV in pregnancy.
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infection in pregnant women,” Archives of Gynecology and
Obstetrics, vol. 284, no. 5, pp. 1105–1112, 2011.
[46] K. Yamasaki, K. Miura, T. Shimada et al., “Epidemiology of hu-
man papillomavirus genotypes in pregnant Japanese women,”
Journal of Human Genetics, vol. 56, no. 4, pp. 313–315, 2011.
[47] B. Dinc, G. Bozdayi, A. Biri et al., “Molecular detection
of cytomegalovirus, herpes simplex virus 2, human papil-
lomavirus 16–18 in Turkish pregnants,” Brazilian Journal of
Infectious Diseases, vol. 14, no. 6, pp. 569–574, 2010.
[48] E. M. Smith, M. A. Parker, L. M. Rubenstein, T. H. Haugen, E.
Hamsikova, and L. P. Turek, “Evidence for vertical transmission
of HPV from mothers to infants,” Infectious Diseases in Obstet-
rics and Gynecology, vol. 2010, Article ID 326369, 7 pages, 2010.
[49] S. M. M. Pereira, D. Etlinger, L. S. Aguiar, S. V. Peres, and
A. Longatto Filho, “Simultaneous Chlamydia trachomatis and
HPV infection in pregnant women,” Diagnostic Cytopathology,
vol. 38, no. 6, pp. 397–401, 2010.
[50] L. B. Freitas, C. C. Pereira, R. Checon, J. P. G. Leite, J. P.
Nascimento, and L. C. Spano, “Adeno-associated virus and
human papillomavirus types in cervical samples of pregnant
and non-pregnant women,” European Journal of Obstetrics
Gynecology and Reproductive Biology, vol. 145, no. 1, pp. 41–44,
2009.
[51] X. Castellsagué, T. Drudis, M. P. Cañadas et al., “Human Papil-
lomavirus (HPV) infection in pregnant women and mother-
to-child transmission of genital HPV genotypes: a prospective
study in Spain,” BMC Infectious Diseases, vol. 9, article 74, 2009.
[52] K. Takakuwa, T. Mitsui, M. Iwashita et al., “Studies on the
prevalence of human papillomavirus in pregnant women in
Japan,” Journal of Perinatal Medicine, vol. 34, no. 1, pp. 77–79,
2006.
[53] M. T. Ruffin IV, J. M. Bailey, D. Roulston et al., “Human papillo-
mavirus in amniotic fluid,” BMC Pregnancy and Childbirth, vol.
6, article 28, 2006.
[54] C. Hernández-Girón, J. S. Smith, A. Lorincz, E. Lazcano, M.
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